Please assess the completion status of the following clinical trial:

Trial Title: RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Relapsing Remitting MS according to the 2017 revised McDonald cri-teria 27 OR one demyelinating episode in conjunction with at least one asympto-matic high intensity T2 lesion with size and location compatible with MS.~* Untreated OR treated with first-line injectables (interferon or glatiramer acetate)~* Between the age of 18 and 50 years (inclusive) of age~* No more than ten years of disease duration~* During the previous year, clinical or radiological disease activity defined as at least one of the following:~  * ≥ 1 relapse~ * ≥ 2 T2 lesions~ * ≥ 1 Gd+ lesions~* Expanded Disability Status Scale: 0 - 5,5 (inclusive)~* In fertile females, willing to comply with effective contraceptive methods. These include birth control pills, surgical sterilization of patient or partner or intrauterine device. Non-fertile women is defined as more than 12 months of amenorrhea without an alternative medical cause or, in case of ambiguities, an follicle stimulation hormone level in the postmenopausal range.~Exclusion Criteria:~* Diagnosis of Progressive MS~* Pregnant or lactating women: human chorionic gonadotropin (s-HCG) will be tested on all women at screening, before each study-related infusion and in any situation where there is a reason to suspect pregnancy during the trial, eg delayed menstrual period more than five days above expected time.~* Patients having contraindication for or otherwise not compliant with MRI investigations~* Simultaneous treatment with other immunosuppressive drugs~* Active, severe infections Signs of infections are assessed before inclusion and each study-related infusion through clinical examination and further evaluated by laboratory and other relevant investigations in case of suspected ongoing infection. Hepatitis serology (HBsAg and anti-HBc) will be evaluated before treatment onset.~* Severe cardiac disorder, eg signs of congestive heart failure or coronary artery disease. This will be evaluated through clinical assessment before inclusion.~* Vaccination within 4 weeks of first dose of study medication.~* Documented allergy or intolerance to any of the investigational products.~* Severe psychiatric condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: EXPERIMENTAL): Infusion of Mabthera/Rituximab every 6 months
- Dimethyl Fumarate (Type: ACTIVE_COMPARATOR): Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.
- Sodium Chloride solution (Type: SHAM_COMPARATOR): Sham infusion with sodium chloride solution for the Tecfidera/Dimethyl Fumarate arm every 6 months (so that the examining physician will be blinded)

Based on this trial design, predict the completion outcome and termination type (if applicable).